MAIA Biotechnology (MAIA) EBITDA (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly EBITDA of -$6.9 million for Q1 2026, down 28.1% year-over-year from -$9.7 million in Q1 2025, and down 60.98% quarter-over-quarter from -$4.3 million in Q4 2025.
MAIA Biotechnology (MAIA) EBITDA (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported EBITDA for 6 consecutive years, with -$6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 28.1% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$25.8 million (down 39.93% YoY), while the FY2025 annual figure was -$24.3 million, down 43.12% from the prior year.
- EBITDA slipped to -$6.9 million in Q1 2026 per MAIA's latest filing, from -$4.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$3.4 million in Q2 2022 and bottomed at -$9.4 million in Q3 2025.
- Historically, EBITDA has averaged -$5.0 million across 5 years, with a median of -$4.7 million in 2023.
- Annual changes were most pronounced in 2022 — EBITDA slumped 128.17% — and 2024, when it rose 21.53%.
- MAIA Biotechnology's EBITDA stood at -$4.2 million in 2022, then plunged by 52.03% to -$6.4 million in 2023, then grew by 21.53% to -$5.0 million in 2024, then grew by 13.73% to -$4.3 million in 2025, then sank by 60.98% to -$6.9 million in 2026.
- Business Quant data shows MAIA's EBITDA at -$6.9 million in Q1 2026, -$4.3 million in Q4 2025, and -$9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.32 Mn |
| Mar 31, 2026 | -6.95 Mn |
| Dec 31, 2025 | -4.32 Mn |
| Sep 30, 2025 | -9.36 Mn |
| Jun 30, 2025 | -5.17 Mn |
| Mar 31, 2025 | -5.43 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Sep 30, 2024 | -4.19 Mn |
| Jun 30, 2024 | -3.82 Mn |
| Mar 31, 2024 | -3.95 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -4.96 Mn |
| Jun 30, 2023 | -4.66 Mn |
| Mar 31, 2023 | -4.18 Mn |
| Dec 31, 2022 | -4.20 Mn |
| Sep 30, 2022 | -5.10 Mn |
| Jun 30, 2022 | -3.44 Mn |
| Mar 31, 2022 | -3.44 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -2.23 Mn |